The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4
Abstract
The inflammatory toxicity of lipopolysaccharide (LPS), a component of bacterial cell walls, is driven by the adaptor proteins myeloid differentiation factor 88 (MyD88) and Toll-interleukin 1 receptor domain–containing adapter inducing interferon-β (TRIF), which together mediate signaling by the endotoxin receptor Toll-like receptor 4 (TLR4). Monophosphoryl lipid A (MPLA) is a low-toxicity derivative of LPS with useful immunostimulatory properties, which is nearing regulatory approval for use as a human vaccine adjuvant. We report here that, in mice, the low toxicity of MPLA's adjuvant function is associated with a bias toward TRIF signaling, which we suggest is likely caused by the active suppression, rather than passive loss, of proinflammatory activity of this LPS derivative. This finding may have important implications for the development of future vaccine adjuvants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway
Yamamoto, M., Sato, S., Hemmi, H., Hoshino, K., Kaisho, T., Sanjo, H., Takeuchi, O., Sugiyama, M., Okabe, M., Takeda, K., et al. (2003) · Science · doi:10.1126/science.1087262 · Cited by 3,235
T cell receptor antagonist peptides induce positive selection
Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J., & Carbone, F. R. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 2,858
IRF-7 is the master regulator of type-I interferon-dependent immune responses
Honda, K., Yanai, H., Negishi, H., Asagiri, M., Sato, M., Mizutani, T., Shimada, N., Ohba, Y., Takaoka, A., Yoshida, N., et al. (2005) · Nature · doi:10.1038/nature03464 · Cited by 2,245
Unresponsiveness of MyD88-Deficient Mice to Endotoxin
Kawai, T., Adachi, O., Ogawa, T., Takeda, K., & Akira, S. (1999) · Immunity · doi:10.1016/s1074-7613(00)80086-2 · Cited by 2,076
Harper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A.-B., Romanowski, B., Roteli-Martins, C. M., Jenkins, D., Schuind, A., Costa Clemens, S. A., & Dubin, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68439-0 · Cited by 1,632
Barnden, M. J., Allison, J., Heath, W. R., & Carbone, F. R. (1998) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.1998.00709.x · Cited by 1,489
Innate immune sensing and its roots: the story of endotoxin
Beutler, B., & Rietschel, E. T. (2003) · Nature Reviews Immunology · doi:10.1038/nri1004 · Cited by 1,391
Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction
Fitzgerald, K. A., Palsson-McDermott, E. M., Bowie, A. G., Jefferies, C. A., Mansell, A. S., Brady, G., Brint, E., Dunne, A., Gray, P., Harte, M. T., et al. (2001) · Nature · doi:10.1038/35092578 · Cited by 1,256
Identification of Lps2 as a key transducer of MyD88-independent TIR signalling
Hoebe, K., Du, X., Georgel, P., Janssen, E., Tabeta, K., Kim, S. O., Goode, J., Lin, P., Mann, N., Mudd, S., et al. (2003) · Nature · doi:10.1038/nature01889 · Cited by 1,231
Kawai, T., Takeuchi, O., Fujita, T., Inoue, J.-I., Mühlradt, P. F., Sato, S., Hoshino, K., & Akira, S. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.10.5887 · Cited by 1,095
Cited by
Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses
Mogensen, T. H. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-08 · Cited by 3,111
The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex
Park, B. S., Song, D. H., Kim, H. M., Choi, B.-S., Lee, H., & Lee, J.-O. (2009) · Nature · doi:10.1038/nature07830 · Cited by 2,428
Signaling to NF-κB by Toll-like receptors
Kawai, T., & Akira, S. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.09.002 · Cited by 2,388
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery
Fang, R. H., Hu, C.-M. J., Luk, B. T., Gao, W., Copp, J. A., Tai, Y., O’Connor, D. E., & Zhang, L. (2014) · Nano Letters · doi:10.1021/nl500618u · Cited by 1,501
Recognition of lipopolysaccharide pattern by TLR4 complexes
Park, B. S., & Lee, J.-O. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.97 · Cited by 1,234
Immunological mechanisms of vaccination
Pulendran, B., & Ahmed, R. (2011) · Nature Immunology · doi:10.1038/ni.2039 · Cited by 1,089
Programming the magnitude and persistence of antibody responses with innate immunity
Kasturi, S. P., Skountzou, I., Albrecht, R. A., Koutsonanos, D., Hua, T., Nakaya, H. I., Ravindran, R., Stewart, S., Alam, M., Kwissa, M., et al. (2011) · Nature · doi:10.1038/nature09737 · Cited by 975
Targeting Toll-like receptors: emerging therapeutics?
Hennessy, E. J., Parker, A. E., & O'Neill, L. A. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3203 · Cited by 886
Applications of nanotechnology for immunology
Smith, D. M., Simon, J. K., & Baker Jr, J. R. (2013) · Nature Reviews Immunology · doi:10.1038/nri3488 · Cited by 767
Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 758
Longhi, M. P., Trumpfheller, C., Idoyaga, J., Caskey, M., Matos, I., Kluger, C., Salazar, A. M., Colonna, M., & Steinman, R. M. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090247 · Cited by 663
TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines
Ishii, K. J., Kawagoe, T., Koyama, S., Matsui, K., Kumar, H., Kawai, T., Uematsu, S., Takeuchi, O., Takeshita, F., Coban, C., et al. (2008) · Nature · doi:10.1038/nature06537 · Cited by 628
Macrophage activation by endogenous danger signals
Zhang, X., & Mosser, D. (2008) · The Journal of Pathology · doi:10.1002/path.2284 · Cited by 611
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00007-1 · Cited by 594
Fortifying the barrier: the impact of lipid A remodelling on bacterial pathogenesis
Needham, B. D., & Trent, M. S. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3047 · Cited by 565
Moon, J. J., Suh, H., Bershteyn, A., Stephan, M. T., Liu, H., Huang, B., Sohail, M., Luo, S., Ho Um, S., Khant, H., et al. (2011) · Nature Materials · doi:10.1038/nmat2960 · Cited by 564
Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant
Casella, C. R., & Mitchell, T. C. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8228-6 · Cited by 560
Self-citationLancaster, G. I., Langley, K. G., Berglund, N. A., Kammoun, H. L., Reibe, S., Estevez, E., Weir, J., Mellett, N. A., Pernes, G., Conway, J. R. W., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.014 · Cited by 466
Modern Subunit Vaccines: Development, Components, and Research Opportunities
Moyle, P. M., & Toth, I. (2013) · ChemMedChem · doi:10.1002/cmdc.201200487 · Cited by 464
Tomchuck, S. L., Zwezdaryk, K. J., Coffelt, S. B., Waterman, R. S., Danka, E. S., & Scandurro, A. B. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0563 · Cited by 449
Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer
O’Neill, L. A. J., Bryant, C. E., & Doyle, S. L. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001073 · Cited by 427
Kim, E., Erdos, G., Huang, S., Kenniston, T. W., Balmert, S. C., Carey, C. D., Raj, V. S., Epperly, M. W., Klimstra, W. B., Haagmans, B. L., et al. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102743 · Cited by 404
The molecular basis of the host response to lipopolysaccharide
Bryant, C. E., Spring, D. R., Gangloff, M., & Gay, N. J. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2266 · Cited by 391
Outer membrane vesicles as platform vaccine technology
van der Pol, L., Stork, M., & van der Ley, P. (2015) · Biotechnology Journal · doi:10.1002/biot.201400395 · Cited by 378
Professional Memory CD4+ T Lymphocytes Preferentially Reside and Rest in the Bone Marrow
Tokoyoda, K., Zehentmeier, S., Hegazy, A. N., Albrecht, I., Grün, J. R., Löhning, M., & Radbruch, A. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.015 · Cited by 352
Heme on innate immunity and inflammation
Dutra, F. F., & Bozza, M. T. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00115 · Cited by 351
Twelve immunotherapy drugs that could cure cancers
‘Mac’ Cheever, M. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00604.x · Cited by 341
Structural Biology of the Toll-Like Receptor Family
Kang, J. Y., & Lee, J.-O. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-052909-141507 · Cited by 331
Trial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 326
Werninghaus, K., Babiak, A., Groß, O., Hölscher, C., Dietrich, H., Agger, E. M., Mages, J., Mocsai, A., Schoenen, H., Finger, K., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081445 · Cited by 315
Coler, R. N., Bertholet, S., Moutaftsi, M., Guderian, J. A., Windish, H. P., Baldwin, S. L., Laughlin, E. M., Duthie, M. S., Fox, C. B., Carter, D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016333 · Cited by 312
Biomaterials for Nanoparticle Vaccine Delivery Systems
Sahdev, P., Ochyl, L. J., & Moon, J. J. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1419-y · Cited by 310
Toll-Like Receptor Agonists in Cancer Therapy
Adams, S. (2009) · Immunotherapy · doi:10.2217/imt.09.70 · Cited by 310
Slingluff, C. L. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318233e5b2 · Cited by 299
Vaccine adjuvants: Current challenges and future approaches
Wilson-Welder, J. H., Torres, M. P., Kipper, M. J., Mallapragada, S. K., Wannemuehler, M. J., & Narasimhan, B. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21523 · Cited by 296
Adjuvants: Classification,Modus Operandi, and Licensing
Apostólico, J. D. S., Lunardelli, V. A. S., Coirada, F. C., Boscardin, S. B., & Rosa, D. S. (2016) · Journal of Immunology Research · doi:10.1155/2016/1459394 · Cited by 287
Therapeutic Cancer Vaccines: Current Status and Moving Forward
Schlom, J. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs033 · Cited by 282
Recognition of lipid A variants by the TLR4-MD-2 receptor complex
Maeshima, N., & Fernandez, R. C. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00003 · Cited by 280
Toll‐like receptors: the swiss army knife of immunity and vaccine development
Dowling, J. K., & Mansell, A. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.22 · Cited by 273
Activating a collaborative innate-adaptive immune response to control metastasis
Sun, L., Kees, T., Almeida, A. S., Liu, B., He, X.-Y., Ng, D., Han, X., Spector, D. L., McNeish, I. A., Gimotty, P., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.005 · Cited by 267
Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action
Pifferi, C., Fuentes, R., & Fernández-Tejada, A. (2021) · Nature Reviews Chemistry · doi:10.1038/s41570-020-00244-3 · Cited by 265
Hem, S. L., & HogenEsch, H. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.685 · Cited by 264
How Do Adjuvants Work? Important Considerations for New Generation Adjuvants
McKee, A. S., Munks, M. W., & Marrack, P. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.003 · Cited by 263
Immunosenescence of microglia and macrophages: impact on the ageing central nervous system
Rawji, K. S., Mishra, M. K., Michaels, N. J., Rivest, S., Stys, P. K., & Yong, V. W. (2016) · Brain · doi:10.1093/brain/awv395 · Cited by 252
Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., López-Deber, M. P., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072301 · Cited by 259
“The likely mechanism involves TLR4 and TRIF-signaling on B-lymphocytes, obviating negative effects of other forms of lipid A that can induce additional inflammatory responses [24,45,46].”
BackgroundMichaud, J.-P., Hallé, M., Lampron, A., Thériault, P., Préfontaine, P., Filali, M., Tribout-Jover, P., Lanteigne, A.-M., Jodoin, R., Cluff, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215165110 · Cited by 252
Cationic lipids activate intracellular signaling pathways
Lonez, C., Vandenbranden, M., & Ruysschaert, J.-M. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.05.009 · Cited by 221
Dysregulation of human Toll-like receptor function in aging
Shaw, A. C., Panda, A., Joshi, S. R., Qian, F., Allore, H. G., & Montgomery, R. R. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2010.10.007 · Cited by 215
Sensing Gram-Negative Bacterial Lipopolysaccharides: a Human Disease Determinant?
Munford, R. S. (2008) · Infection and Immunity · doi:10.1128/iai.00939-07 · Cited by 189
Kwissa, M., Nakaya, H. I., Oluoch, H., & Pulendran, B. (2012) · Blood · doi:10.1182/blood-2011-10-388579 · Cited by 132
Matsumoto, M., Tatematsu, M., Nishikawa, F., Azuma, M., Ishii, N., Morii-Sakai, A., Shime, H., & Seya, T. (2015) · Nature Communications · doi:10.1038/ncomms7280 · Cited by 130
Prophylactic and therapeutic implications of toll-like receptor ligands
Hedayat, M., Takeda, K., & Rezaei, N. (2012) · Medicinal Research Reviews · doi:10.1002/med.20214 · Cited by 76
Contribution of Toll-like receptor signaling to germinal center antibody responses
DeFranco, A. L., Rookhuizen, D. C., & Hou, B. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01115.x · Cited by 74
Trends in adjuvant development for vaccines: DAMPs and PAMPs as potential new adjuvants
Miyaji, E. N., Carvalho, E., Oliveira, M. L. S., Raw, I., & Ho, P. L. (2011) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2011007500064 · Cited by 66
“It is interesting to note that while binding of LPS to TLR4 activates both the MyD88-TIRAP and TRIF-TRAM pathways (Figure 2), MPL was shown to activate only the TRIFTRAM pathway, which accounts for its adjuvant properties and low toxicity (23).”
BackgroundChang, T. T., Spurlock, S. M., Candelario, T. L. T., Grenon, S. M., & Hughes‐Fulford, M. (2015) · The FASEB Journal · doi:10.1096/fj.15-275073 · Cited by 42
Strategies for Small Extracellular Vesicle-Based Cancer Immunotherapy
Chen, Y., Tang, S., Cai, F., & Wan, Y. (2024) · Research · doi:10.34133/research.0421 · Cited by 26
Innovative Vaccine Strategy: Self-Adjuvanting Conjugate Vaccines
Manabe, Y., & Fukase, K. (2023) · Methods in Molecular Biology · doi:10.1007/978-1-0716-2910-9_5 · Cited by 5
Metadata
- Authors
- Mata-Haro, V., Cekic, C., Martin, M., Chilton, P. M., Casella, C. R., & Mitchell, T. C.
- Venue
- Science
- Published
- 2007-06-15
- Volume
- 316
- Issue
- 5831
- Pages
- 1628-1632
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2128897591
- Cited by
- 896
- References
- 26
- FWCI
- 14.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.